Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML models with activating FLT3 mutations.
作者信息
Miao Hongzhi, Kim EunGi, Chen Dong, Purohit Trupta, Kempinska Katarzyna, Ropa James, Klossowski Szymon, Trotman Winifred, Danet-Desnoyers Gwenn, Cierpicki Tomasz, Grembecka Jolanta
机构信息
Department of Pathology, University of Michigan, Ann Arbor, MI.
Department of Microbiology and Immunology, School of Medicine, Indiana University, Indianapolis, IN; and.
出版信息
Blood. 2020 Dec 17;136(25):2958-2963. doi: 10.1182/blood.2020006575.
Abstract
摘要
相似文献
1
Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML models with activating FLT3 mutations.使用Menin和FLT3抑制剂的联合治疗在具有激活型FLT3突变的急性髓系白血病模型中诱导完全缓解。
Blood. 2020 Dec 17;136(25):2958-2963. doi: 10.1182/blood.2020006575.
2
Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.通过 menin-MLL 和 FLT3 联合抑制协同靶向 AML 中的 FLT3 突变。
Blood. 2020 Nov 19;136(21):2442-2456. doi: 10.1182/blood.2020005037.
3
Targeting FLT3 for the treatment of leukemia.靶向FLT3治疗白血病。
Semin Hematol. 2008 Jul;45(3 Suppl 2):S17-21. doi: 10.1053/j.seminhematol.2008.07.007.
4
Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors.联合治疗克服突变型 FLT3 阳性 AML 中的基质介导的化疗耐药性：FLT3 抑制剂、达沙替尼/多靶点抑制剂和 JAK 抑制剂的协同作用。
Leukemia. 2012 Oct;26(10):2233-44. doi: 10.1038/leu.2012.96. Epub 2012 Apr 3.
5
A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML.一项关于在FLT3突变的急性髓系白血病一线化疗中添加激酶抑制剂来那度胺的随机评估。 （注：原文中lestaurtinib应为lestaurtinib，译文已修正）
Blood. 2017 Mar 2;129(9):1143-1154. doi: 10.1182/blood-2016-07-730648. Epub 2016 Nov 21.
6
Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.帕博西尼治疗FLT3-ITD+急性髓系白血病细胞揭示了CDK6对FLT3和PIM1的激酶依赖性转录调控。
Blood. 2016 Jun 9;127(23):2890-902. doi: 10.1182/blood-2015-11-683581. Epub 2016 Apr 20.
7
Will newer tyrosine kinase inhibitors have an impact in AML?新型酪氨酸激酶抑制剂对 AML 有影响吗？
Best Pract Res Clin Haematol. 2010 Dec;23(4):489-94. doi: 10.1016/j.beha.2010.09.008. Epub 2010 Nov 5.
8
FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance.FLT3 抑制剂在急性髓系白血病中的应用：疗效和耐药机制的综述。
Int J Hematol. 2013 Jun;97(6):683-94. doi: 10.1007/s12185-013-1334-8. Epub 2013 Apr 24.
9
Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.克立替尼对耐药性 FLT3-ITD 阳性急性髓细胞性白血病模型具有活性。
Blood. 2013 Nov 21;122(22):3607-15. doi: 10.1182/blood-2013-07-513044. Epub 2013 Sep 17.
10
Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challenges.对表达活化型FMS样酪氨酸激酶3（FLT3）的白血病进行治疗干预：机遇与挑战。
Curr Opin Hematol. 2005 Jan;12(1):7-13. doi: 10.1097/01.moh.0000147891.06584.d7.
引用本文的文献
1
Menin in Cancer.Menin 在癌症中的作用。
Genes (Basel). 2024 Sep 21;15(9):1231. doi: 10.3390/genes15091231.
2
A menin-KMT2A inhibitor to overcome resistance.一种克服耐药性的Menin-KMT2A抑制剂。
Blood. 2024 Sep 12;144(11):1139-1140. doi: 10.1182/blood.2024025760.
3
Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias.强效、选择性的 menin-KMT2A 抑制剂 JNJ-75276617（bleximenib）在 KMT2A 和 NPM1 改变的白血病中的临床前疗效。
Blood. 2024 Sep 12;144(11):1206-1220. doi: 10.1182/blood.2023022480.
4
Combination of menin and kinase inhibitors as an effective treatment for leukemia with NUP98 translocations.联合使用 menin 和激酶抑制剂治疗 NUP98 易位白血病的有效方法。
Leukemia. 2024 Aug;38(8):1674-1687. doi: 10.1038/s41375-024-02312-9. Epub 2024 Jun 18.
5
Therapeutic targeting in pediatric acute myeloid leukemia with aberrant HOX/MEIS1 expression.治疗靶向治疗伴有异常 HOX/MEIS1 表达的小儿急性髓系白血病。
Eur J Med Genet. 2023 Dec;66(12):104869. doi: 10.1016/j.ejmg.2023.104869. Epub 2023 Oct 29.
6
The MLL-Menin Interaction is a Therapeutic Vulnerability in -rearranged AML.MLL与Menin的相互作用是MLL重排急性髓系白血病中的一个治疗弱点。
Hemasphere. 2023 Jul 27;7(8):e935. doi: 10.1097/HS9.0000000000000935. eCollection 2023 Aug.
7
Genetic, Phenotypic, and Clinical Heterogeneity of NPM1-Mutant Acute Myeloid Leukemias.NPM1突变型急性髓系白血病的遗传、表型及临床异质性
Biomedicines. 2023 Jun 24;11(7):1805. doi: 10.3390/biomedicines11071805.
8
Advances in molecular characterization of pediatric acute megakaryoblastic leukemia not associated with Down syndrome; impact on therapy development.非唐氏综合征相关小儿急性巨核细胞白血病的分子特征研究进展；对治疗发展的影响
Front Cell Dev Biol. 2023 Jun 1;11:1170622. doi: 10.3389/fcell.2023.1170622. eCollection 2023.
9
Novel Investigational Agents and Pathways That May Influence the Future Management of Acute Myeloid Leukemia.可能影响急性髓系白血病未来治疗的新型研究药物和途径
Cancers (Basel). 2023 May 29;15(11):2958. doi: 10.3390/cancers15112958.
10
Targeting FLT3 Mutation in Acute Myeloid Leukemia: Current Strategies and Future Directions.靶向急性髓系白血病中的FLT3突变：当前策略与未来方向
Cancers (Basel). 2023 Apr 15;15(8):2312. doi: 10.3390/cancers15082312.
本文引用的文献
1
Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.通过 menin-MLL 和 FLT3 联合抑制协同靶向 AML 中的 FLT3 突变。
Blood. 2020 Nov 19;136(21):2442-2456. doi: 10.1182/blood.2020005037.
2
Therapeutic targeting of preleukemia cells in a mouse model of mutant acute myeloid leukemia.在一个突变型急性髓系白血病的小鼠模型中对白血病前细胞进行治疗性靶向。
Science. 2020 Jan 31;367(6477):586-590. doi: 10.1126/science.aax5863.
3
Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia.Menin 抑制剂 MI-3454 诱导 MLL1 重排和 NPM1 突变的白血病模型缓解。
J Clin Invest. 2020 Feb 3;130(2):981-997. doi: 10.1172/JCI129126.
4
A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia.一种 Menin-MLL 抑制剂可诱导特定的染色质变化，并消除 MLL 重排白血病模型中的疾病。
Cancer Cell. 2019 Dec 9;36(6):660-673.e11. doi: 10.1016/j.ccell.2019.11.001.
5
FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development.急性髓系白血病中的 FLT3 突变：超越抑制剂开发的治疗范例。
Cancer Sci. 2020 Feb;111(2):312-322. doi: 10.1111/cas.14274. Epub 2019 Dec 30.
6
Prognosis and outcome of patients with acute myeloid leukemia based on mutation with or without additional abnormal cytogenetics.基于伴有或不伴有其他细胞遗传学异常的突变的急性髓系白血病患者的预后和结局
Oncol Lett. 2019 Dec;18(6):6766-6774. doi: 10.3892/ol.2019.11051. Epub 2019 Nov 5.
7
Targeting FLT3 mutations in AML: review of current knowledge and evidence.AML 中 FLT3 突变的靶向治疗：现有知识和证据的综述。
Leukemia. 2019 Feb;33(2):299-312. doi: 10.1038/s41375-018-0357-9. Epub 2019 Jan 16.
8
Complexity of Blocking Bivalent Protein-Protein Interactions: Development of a Highly Potent Inhibitor of the Menin-Mixed-Lineage Leukemia Interaction.阻断双价蛋白-蛋白相互作用的复杂性：Menin-Mixed-Lineage Leukemia 相互作用的高效抑制剂的开发。
J Med Chem. 2018 Jun 14;61(11):4832-4850. doi: 10.1021/acs.jmedchem.8b00071. Epub 2018 May 23.
9
Clustering Algorithms: Their Application to Gene Expression Data.聚类算法：它们在基因表达数据中的应用。
Bioinform Biol Insights. 2016 Nov 30;10:237-253. doi: 10.4137/BBI.S38316. eCollection 2016.
10
Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia.靶向染色质调节因子可抑制NPM1突变型白血病中的白血病致病基因表达。
Cancer Discov. 2016 Oct;6(10):1166-1181. doi: 10.1158/2159-8290.CD-16-0237. Epub 2016 Aug 17.
Zotero 插件